



Sixth Meeting of the RBM Partnership  
Case Management Working Group (CMWG)

11<sup>th</sup> – 13<sup>th</sup> June 2012  
Geneva, Switzerland

Participant List

	Institution	Names	Email	Work stream
1	RBM	Thomas Teuscher	teuschert@who.int	
2	TDR (CMWG Co-Chair)	Franco Pagnoni	pagnonif@who.int	Expanding Access to Treatment
3	CDC (CMWG Co-Chair)	Patrick Kachur	spko@cdc.gov	Expanding Access to Treatment
4	Core Group (Co-focal point)	Shannon Downey	sdowney@coregroupdc.org	Expanding Access to Treatment
5	PMI (Focal point)	Lawrence Barat	lbarat@usaid.gov	Diagnosis
6	WHO/GMP (Co-focal point)	Pascal Ringwald	ringwaldp@who.int	Drug Resistance
7	Malaria Consortium (Co-focal point)	Sylvia Meek	s.meek@malariaconsortium.org	Drug Resistance
8	Accordia Foundation	Kelly Willis	kwillis@accordiafoundation.org	Expanding Access to Treatment
9	ACT Consortium	Toby Leslie	Toby.Leslie@lshtm.ac.uk	Diagnosis
10	CDC	Laura Steinhardt	iyp6@cdc.gov	Expanding Access to treatment
11	CDC	Eugenie Poirot	irh9@cdc.gov	Expanding Access to Treatment
12	Clinton Health Access Initiative	Alexandra Morris	amorris@clintonhealthaccess.org	
13	Clinton Health Access Initiative	Nora Petty	npetty@clintonHealthAccess.org	Diagnosis
14	NMCP, Cambodia	Ly Po	poly@cnm.gov.kh	
15	NMCP, DRC	Benjamin Matindii Atua	atuabenjamin@gmail.com	
16	NMCP, Malawi	John Sande	jhsande@yahoo.com	
17	NMCP, Nigeria	Godwin Ntadom	ntadomg@yahoo.com	
18	NMCP, Zanzibar	Mwinyi Msellem	mmwinyi@hotmail.com	Diagnosis
19	Malaria Consortium	Elizabeth Streat	E.Streat@malariaconsortium.org	Diagnosis
20	Malaria Consortium	Kirsty Buchanan	k.buchanan@malariaconsortium.org	
21	Malaria Consortium	Prudence Hamade	p.hamade@malariaconsortium.org	Diagnosis / Expanding Access to Treatment
22	Malaria Consortium (SuNMaP)	Ebenezer Baba	e.baba@malariaconsortium.org	
23	Medical Care Development International	Luis Benavente	lbenavente@mcd.org	Diagnosis

24	Medicines for Malaria Venture	Renia Coghlan	coghlanr@mmv.org	
25	Medicines for Malaria Venture	George Jagoeg	jagoeg@mmv.org	
26	Medicines for Malaria Venture	Penny Grewal	grewalp@mmv.org	Expanding Access to Treatment
27	Medicines for Malaria Venture	Pierre Hugo	hugop@mmv.org	
28	Medicines for Malaria Venture	Stephan Duparc	duparcs@mmv.org	
29	Médecins Sans Frontières	Martin De Smet	martin.de.smet@brussels.msf.org	Diagnosis
30	Novartis	Paul Aliu	paul.aliu@novartis.com	
31	PSI	Victor Lara	victor@psi.org	
32	PSI	Yves Cyaka	ycyaka@psi.org	
33	RBM	Jan Van Erps	VanErpsJ@who.int	Diagnosis
34	RBM	Magali Babaley	babaleym@who.int	
35	Sanofi-aventis	Andre Tchouatieu	Andre.Tchouatieu@sanofi-aventis.com	
36	Swiss Tropical & Public Health Institute	Valerie Dacremont	Valerie.Dacremont@unibas.ch	Diagnosis
37	WHO/AFRO	Josephine Namboze	nambozej@zw.afro.who.int	Expanding Access to Treatment
38	WHO/GMP	Andrea Bosman	bosmana@who.int	Diagnosis
39	WHO/GMP	Peter Olumese	olumesep@who.int	Expanding Access to Treatment
40	WHO/GMP	Richard Cibulskis	cibulskisr@who.int	Co-Chair, RBM Monitoring & Evaluation Reference Group
41	WHO/GMP	Robert Newman	newmanr@who.int	
42	WHO/MCA	Viviana Mangiaterra	mangiaterrav@who.int	Co-Chair, RBM Malaria in Pregnancy Working Group
43	WHO	Shanthi Pal	pals@who.int	Co-chair, Pharmacovigilance work stream, PSMWG
44	WHO	Cathy Wolfheim	wolfheimc@who.int	On behalf of iCCM task force
45	WWARN	Philippe Guerin	philippe.guerin@wwarn.org	Drug Resistance
46	LSHTM	Shunmay Yeung	Shunmay.Yeung@lshtm.ac.uk	Drug Resistance